|
1.
|
|
|
2.
|
|
12 p, 1.3 MB |
Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis : a real-world multicenter experience from Spain
/
Valero-Martínez, Cristina (Hospital Universitario de La Princesa) ;
Urgelles, Judit Font (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Sallés, Meritxell (Althaia Xarxa Assistencial Universitària) ;
Joven-Ibáñez, Beatriz E. (Hospital 12 de Octubre (Madrid)) ;
de Juanes, Alexia (Hospital 12 de Octubre (Madrid)) ;
Ramírez, Julio (Hospital Clínic i Provincial de Barcelona) ;
Juanola, Xavier (Hospital Universitari de Bellvitge) ;
Almodóvar, Raquel (Hospital Universitario Fundación Alcorcón) ;
Laiz, Ana (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Moreno Martínez-Losa, Mireia (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Pujol, Manel (Hospital Universitari MútuaTerrassa) ;
Beltran Catalan, Emma (Hospital del Mar (Barcelona, Catalunya)) ;
Pinto-Tasende, José Antonio (Hospital Universitario de A Coruña) ;
Crespí, Laura (Hospital de Manacor) ;
Sala-Icardo, Luis (Hospital de Torrejón de Ardoz) ;
Castañeda, Santos (Universidad Autónoma de Madrid) ;
García-Vicuña, Rosario (Universidad Autónoma de Madrid) ;
Universitat Autònoma de Barcelona
Dual targeted therapy (DTT) has emerged as a promising approach in patients with refractory spondyloarthritis (SpA) or psoriatic arthritis (PsA) and extra-musculoskeletal manifestations of both diseases, but its effectiveness/safety ratio still remains unclear. [...]
2023 -  10.3389/fimmu.2023.1283251
Frontiers in immunology, Vol. 14 (october 2023)
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
10 p, 825.0 KB |
Neuropeptide-S-receptor deficiency affects sex-specific modulation of safety learning by pre-exposure to electric stimuli
/
Kreutzmann, Judith.C. (Department of Systems Physiology of Learning. Leibniz Institute for Neurobiology) ;
Khalil, Radwa (Otto-von-Guericke University Magdeburg. Institute for Pharmacology & Toxicology) ;
Köhler, Jana C. (Otto-von-Guericke University Magdeburg. Center of Behavioral Brain Sciences) ;
Mayer, Dana (Otto-von-Guericke University Magdeburg. Institute for Pharmacology & Toxicology) ;
Florido Torres, Antonio Luis (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Nadal i Alemany, Roser (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Andero Galí, Raül (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal) ;
Fendt, Markus (Otto-von-Guericke University Magdeburg. Center of Behavioral Brain Sciences)
Neuropeptide S (NPS) is a neuropeptide involved in the regulation of fear. Because safety learning is impaired in patients suffering from anxiety-related psychiatric disorders, and polymorphisms of the human neuropeptide S receptor (NPSR) gene have also been associated with anxiety disorders, we wanted to investigate whether NPSR-deficiency interferes with safety learning, and how prior stress would affect this type of learning. [...]
2020 - 10.1111/gbb.12621
Genes, Brain and Behavior, Vol. 19 Núm. 3 (January 2020) , p. e12621
|
|
|
6.
|
|
7 p, 715.4 KB |
Safety and efficacy of self-administered inhaled loxapine (ADASUVE) in agitated patients outside the hospital setting : Protocol for a phase IV, single-arm, open-label trial
/
Gil, Emilio (Ferrer Internacional. S.A.) ;
Garcia-Alonso, Fernando (Ferrer Internacional. S.A.) ;
Boldeanu, Anca (Ferrer Internacional. S.A.) ;
Baleeiro Teixeira, Thaïs (Ferrer Internacional. S.A.) ;
Tordera, Vicente (Hospital Lluís Alcanyis) ;
Viciedo, Ramón Palmer (Hospital Provincial de Castelló) ;
Salgado Serrano, Dr Purificación (Hospital del Mar (Barcelona, Catalunya)) ;
Domingo Ribas, Jordi (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Corripio, Iluminada (Institut d'Investigació Biomèdica Sant Pau) ;
Montes, José Manuel (Hospital Universitario Ramón y Cajal (Madrid)) ;
Lauffer, Javier Correas (Hospital Univ de Henares) ;
Murugarrem, Salvador Ruiz (Hospital Príncipe de Asturias) ;
García, Santiago Ovejero (Hospital Universitario Fundación Jiménez Díaz) ;
Mora, Fernando (Hospital Universitario Infanta Leonor) ;
López, Presentación Ataz (Complejo Hospitalario Torrecárdenas (Almeria)) ;
Navas, Andrés Fontalba (Hospital la Inmaculada) ;
Pinto, Ana Mª González (Hospital Santiago Apóstol) ;
Martínez, Ricardo (Hospital Virgen Del Mirón) ;
Castrillo, César García (Complejo Hospitalario de Jaen) ;
Toledo, Francisco (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ;
Vieta, Eduard (Hospital Clínic i Provincial de Barcelona) ;
González, Emilio (Hermanas Hospitalarias Sociosanitario Palencia) ;
Franco Martín, Manuel (Complejo Asistencial Zamora) ;
Drasovean, Nicolae Virgil (Spitalul de Psihiatrie 'Elisabeta Doamna' Galati) ;
Dahl, Nils Hâvard (Helse Nord-Trøndelag HV Sykehuset Levanger) ;
Skagen, Bo (Spesialistesenteret På Straume-Helsesenteret) ;
Zilles, David (Klinik Für Psychiatrie und Psychotherapie der Universitätsmedizin Göttingen) ;
Zwanzger, Peter (Allgemeinpsychiatrie und Psychosomatik) ;
Juckel, Georg (LWL-Universitätsklinikum Bochum der Ruhr-Universität Bochum) ;
Kahl, Kai G. (Medizinische Hochschule Hannover) ;
Messer, Thomas (Fachklinik Für Psychiatrie) ;
Kasper, Siegfried (Medizinische Universität Wien Universitätsklinik Für Psychiatrie und Psychotherapie) ;
Universitat Autònoma de Barcelona
There is a need for fast-acting, non-injection antiagitation treatments that are well tolerated and can be used outside of healthcare facilities. In phase II/III trials, an inhaled formulation of loxapine (ADASUVE®), a well-established, first-generation antipsychotic agent, provided rapid control of mild to moderate agitation in the hospital setting. [...]
2018 - 10.1136/bmjopen-2017-020242
BMJ open, Vol. 8 Núm. 10 (january 2018) , p. e020242
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
|
12 p, 484.6 KB |
Safety profile of the adjuvanted recombinant zoster vaccine : Pooled analysis of two large randomised phase 3 trials
/
López Fauqued, Marta (GlaxoSmithKline (GSK)) ;
Campora, Laura (GlaxoSmithKline (GSK)) ;
Delannois, Frédérique (GlaxoSmithKline (GSK)) ;
El Idrissi, Mohamed (GlaxoSmithKline (GSK)) ;
Oostvogels, Lidia (GlaxoSmithKline (GSK)) ;
De Looze, Ferdinandus (University of Queensland) ;
Diez-Domingo, Javier (Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat (València)) ;
Heineman, Thomas (GlaxoSmithKline (GSK)) ;
Lal, Himal (GlaxoSmithKline (GSK)) ;
McElhaney, Janet (Health Sciences North Research Institute) ;
McNeil, Shelly (Dalhousie University) ;
Yeo, Wilfred (University of Wollongong) ;
Tavares-Da-Silva, Fernanda (GlaxoSmithKline (GSK)) ;
Ahonen, Anitta (University of Tampere) ;
Avelino-Silva, Thiago (University of São Paulo Medical School) ;
Barba-Gomez, José Fernando (Instituto Dermatológico de Jalisco) ;
Berglund, Johan (Blekinge Institute of Technology) ;
Brotons, Carlos (Institut d'Investigació Biomèdica Sant Pau) ;
Caso, Covadonga (Hospital Clínico San Carlos (Madrid)) ;
Chlibek, Roman (University of Defence) ;
Choi, Won Suk (Korea University College of Medicine) ;
Cunningham, Anthony (University of Sydney) ;
Desole, Maria Giuseppina (Servizio di Igiene Pubblica) ;
Eizenberg, Peter (Doctors of Ivanhoe) ;
Esen, Meral (University Clinic of Tübingen) ;
Espié, Emmanuelle (GlaxoSmithKline (GSK)) ;
Gervais, Pierre (Q&T Research Sherbrooke) ;
Ghesquiere, Wayne (University of British Columbia) ;
Godeaux, Olivier O. (GlaxoSmithKline (GSK)) ;
Gorfinkel, Iris (York University) ;
Hui, David Shu Cheong (Prince of Wales Hospital (Australia)) ;
Hwang, Shinnjang (Taipei Veterans General Hospital and National Yang Ming University School of Medicine) ;
Korhonen, Tiina (University of Tampere Medical School) ;
Kovac, Martina (GlaxoSmithKline (GSK)) ;
Ledent, Edouard Y. (GlaxoSmithKline (GSK)) ;
Leung, Edward Man Fuk (Hong Kong Association of Gerontology) ;
Levin, Myron (University of Colorado Anschutz Medical Campus) ;
Perez, Silvia Narejos (CAP Centelles) ;
de Andrade Neto, José Luiz (Instituto A. Z. de Pesquisa e Ensino) ;
Pauksens, Karlis (Uppsala University Hospital) ;
Poder, Airi (Kliiniliste Uuringute Keskus) ;
Rodriguez de la Pinta, Maria Luisa (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Rombo, Lars (Uppsala University) ;
Schwarz, Tino Francis (Standort Juliusspital) ;
Smetana, Jan (University of Defence) ;
Staniscia, Tommaso (University G. d'Annunzio of Chieti-Pescara) ;
Tinoco-Fávila, Juan Carlos (Hospital General de Durango) ;
Toma, Azhar (Manna Research) ;
Vastiau, Ilse (GlaxoSmithKline (GSK)) ;
Vesikari, Timo H. (University of Tampere) ;
Volpi, Antonio (A.O. Univesitaria Policlinico Tor Vergata) ;
Watanabe, Daisuke (Kobe University Graduate School of Medicine) ;
Weckx, Lily (Federal University of Sao Paulo) ;
Zahaf, Toufik (GlaxoSmithKline (GSK)) ;
Universitat Autònoma de Barcelona
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies. [...]
2019 - 10.1016/j.vaccine.2019.03.043
Vaccine, Vol. 37 Núm. 18 (24 2019) , p. 2482-2493
|
|
|
10.
|
|
14 p, 3.8 MB |
Confidence in a Vaccine against COVID-19 among Registered Nurses in Barcelona, Spain across Two Time Periods
/
Palma, David (Institut d'Investigació Biomèdica Sant Pau) ;
Hernández Pineda, Anna (Institut d'Investigació Biomèdica Sant Pau) ;
Picchio, Camila A. (Hospital Clínic i Provincial de Barcelona) ;
Jodar, Glòria (Col·legi Oficial d'Infermeres i Infermers de Barcelona) ;
Galbany Estragues, Paola (Col·legi Oficial d'Infermeres i Infermers de Barcelona) ;
Simón Vivan, Pere (Institut d'Investigació Biomèdica Sant Pau) ;
Guillaumes, Montserrat (Institut d'Investigació Biomèdica Sant Pau) ;
Diez, Elia (Institut d'Investigació Biomèdica Sant Pau) ;
Rius i Gibert, Maria Cristina (Institut d'Investigació Biomèdica Sant Pau)
Objective: To report the vaccine hesitancy (VH) for a vaccine against COVID-19 in registered nurses in Barcelona, with measurements taken at two stages, prior to the vaccination campaign and once 75% vaccination coverage had been reached. [...]
2022 - 10.3390/vaccines10060873
Vaccines (Basel), Vol. 10 Núm. 6 (june 2022) , p. 873
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
